Efficacy and safety of sofosbuvir/velpatasvir in patients with chronic hepatitis C virus infection receiving opioid substitution therapy: Analysis of phase 3 ASTRAL trials

Clinical Infectious Diseases

Volumn 63, Issue 11, 2016, Pages 1479-1481

  Grebely, Jason ^a   Dore, Gregory J ^a   Zeuzem, Stefan ^b   Aspinall, Richard J ^c   Fox, Raymond ^d   Han, Lingling ^e   McNally, John ^e   Osinusi, Anu ^e   Brainard, Diana M ^e   Subramanian, G Mani ^e   Natha, Macky ^e   Foster, Graham R ^f   Mangia, Alessandra ^g   Sulkowski, Mark ^h   Feld, Jordan J ⁱ  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c PORTSMOUTH HOSPITALS NHS TRUST   (United Kingdom)

^d Brownlee Centre   (United Kingdom)

^e GILEAD SCIENCES   (United States)

^f QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^g CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^h JOHNS HOPKINS UNIVERSITY   (United States)

ⁱ Toronto Liver Centre   (Canada)

Author keywords

HCV; OST; PWID; Sofosbuvir; Velpatasvir

Indexed keywords

SOFOSBUVIR PLUS VELPATASVIR; ANTIVIRUS AGENT; CARBAMIC ACID DERIVATIVE; FUSED HETEROCYCLIC RINGS; RIBAVIRIN; SOFOSBUVIR; VELPATASVIR;

ABDOMINAL PAIN; ADULT; ANXIETY; ARTICLE; ATTENTION DISTURBANCE; BRONCHITIS; CHRONIC HEPATITIS C; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SCREENING; DRUG USE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEART PALPITATION; HEPATITIS C VIRUS; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; OPEN STUDY; OPIATE SUBSTITUTION TREATMENT; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SUSTAINED VIROLOGIC RESPONSE; ANTIVIRAL RESISTANCE; BLOOD; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DRUG ADMINISTRATION; DRUG EFFECTS; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; MEDICATION COMPLIANCE; STATISTICAL ANALYSIS; TREATMENT OUTCOME; VIROLOGY;

ADULT; ANTIVIRAL AGENTS; CARBAMATES; DATA INTERPRETATION, STATISTICAL; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HETEROCYCLIC COMPOUNDS, 4 OR MORE RINGS; HUMANS; LIVER CIRRHOSIS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; OPIATE SUBSTITUTION TREATMENT; RIBAVIRIN; SOFOSBUVIR; SUSTAINED VIROLOGIC RESPONSE; TREATMENT OUTCOME;

EID: 85014946203     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciw579     Document Type: Article

References (12)

1. Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol 2013; 10:553-62.
2. Feld JJ, Jacobson IM, Hezode C, et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med 2015; 373:2599-607.
3. Foster GR, Afdhal N, Roberts SK, et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med 2015; 373:2608-17.
4. AASLD/IDSA. Recommendations for testing, managing, and treating hepatitis C. In; 2015. Available at: www.hcvguidelines.org/. Accessed 1 September 2016.
5. Grebely J, Robaeys G, Bruggmann P, et al. Recommendations for the management of hepatitis C virus infection among people who inject drugs. Int J Drug Policy 2015; 26:1028-38.
6. European Association for Study of Liver. EASL recommendations on treatment of hepatitis C 2015. J Hepatol 2015; 63:199-236.
7. Dimova RB, Zeremski M, Jacobson IM, Hagan H, Des Jarlais DC, Talal AH. Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis. Clin Infect Dis 2013; 56:806-16.
8. Aspinall EJ, Corson S, Doyle JS, et al. Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis. Clin Infect Dis 2013; 57(suppl 2):S80-9.
9. Simmons B, Saleem J, Hill A, Riley RD, Cooke GS. Risk of late relapse or reinfection with hepatitis C virus after achieving a sustained virological response: a systematic review and meta-analysis. Clin Infect Dis 2016; 62:683-94.
10. Lalezari J, Sullivan JG, Varunok P, et al. Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine. J Hepatol 2015; 63:364-9.
11. Grebely J, Mauss S, Brown A, et al. Efficacy and safety of sofosbuvir/ledipasvir with and without ribavirin in patients with chronic HCV genotype 1 infection receiving opioid substitution therapy: analysis of phase 3 ION trials. Clin Infect Dis 2016; 63:1405-11.
12. Dore GJ, Altice F, Litwin AH, et al. Elbasvir/grazoprevir to treat HCV infection in persons receiving opioid agonist therapy: a randomized controlled trial (C-EDGE CO-STAR). Ann Intern Med 2016; doi:10.7326/M16-0816.